Concomitant hepatocellular carcinoma recurrence and mantle cell lymphoma

A Pancreatic Collision Tumor Comprising Mantle Cell Lymphoma and Adenocarcinoma: A Case Report and Literature Review

“…Reports on MCL and solid collision neoplasms are presented in Table . In addition to pancreatic cancer ( 4 ), 15 cases of collision tumors of the MCL with cancers of the lung/pleura ( 6 - 10 ), gastrointestinal tract ( 11 , 12 ), liver ( 13 ), breast ( 14 ), penis ( 15 ), and prostate ( 16 ) as well as melanoma of the skin ( 17 - 20 ) have been reported. In most cases, MCL and solid neoplasms are detected synchronously, either within the neoplasm or in the metastatic lymph nodes.…”

“…In most cases, MCL and solid neoplasms are detected synchronously, either within the neoplasm or in the metastatic lymph nodes. However, metachronous cases have occasionally been reported; MCLs preceded in two cases ( 4 , 17 ), and solid neoplasms preceded in two cases ( 13 , 15 ). Similar to our patient, 13% (2/15) of the reported cases were not accompanied by lymphadenopathy during the MCL diagnosis ( 11 , 16 ), 50% (3/6) were accompanied by splenomegaly ( 4 , 13 , 16 ), and 14% (1/7) were accompanied by lymphocytosis ( 18 ) during the MCL diagnosis.…”

“…However, metachronous cases have occasionally been reported; MCLs preceded in two cases ( 4 , 17 ), and solid neoplasms preceded in two cases ( 13 , 15 ). Similar to our patient, 13% (2/15) of the reported cases were not accompanied by lymphadenopathy during the MCL diagnosis ( 11 , 16 ), 50% (3/6) were accompanied by splenomegaly ( 4 , 13 , 16 ), and 14% (1/7) were accompanied by lymphocytosis ( 18 ) during the MCL diagnosis. Regarding the treatment for collision MCL, nine cases received chemotherapy, four were observed without lymphoma chemotherapy, and three had no description.…”

“…After intermittent prednisolone administration, her lymphocyte counts decreased to less than 4,000/μL, and splenomegaly also improved. In addition, 15 months after the diagnosis, the patient presented with abdominal distention and vomit- (20) No specific therapy Immunotherapy 6 MCL is in SD 17 (13) Rituximab-CHOP TACE 5 MCL is in CR; HCC in PR BR: bendamustine and rituximab, CEO(P): cyclophosphamide, epirubicin, vincristine, (and prednisolone), CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisolone, CR: complete remission, FOLFOLINOX: oxaliplatin: irinotecan: fluorouracil, and leucovorin, Hyper CVAD: cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, and cytarabine, MCL: mantle cell lymphoma, NR: not reported, PD: progressive disease, PR: partial remission, SD: stable disease, TACE: transcatheter arterial chemoembolization * Lymphocytosis was defined by an increase in lymphocyte counts ≥4.0×10 3 /μL ** For alleviating symptoms ing due to duodenal ileus, which improved by receiving 125 mg intravenous methylprednisolone (IVMP) once. One month later, the duodenal ileus recurred and improved with 125 mg IVMP therapy for 2 days.…”